Viewing Study NCT01234857


Ignite Creation Date: 2025-12-24 @ 6:31 PM
Ignite Modification Date: 2026-02-10 @ 11:39 PM
Study NCT ID: NCT01234857
Status: COMPLETED
Last Update Posted: 2017-05-31
First Post: 2010-09-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module References Module